Intrexon | XON - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Agenus USD 10.56M 13.04M 2025-12
Alaunos Therapeutics USD 585K 84K 2025-09
Amgen USD 1.94B 237M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 390.41M 61.33M 2025-12
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 29.09M 2.53M 2025-09
Merck USD 2.85B 215M 2025-12
Novartis USD 3.44B 128M 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Thermo Fisher Scientific USD 1.98B 182M 2025-12
Veracyte USD 43.31M 8.43M 2025-12
Xencor USD 17.04M 70.74M 2025-12